The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion

Coras, Roland, Hoelsken, Annett, Seufert, Sebastian, Hauke, Jan, Eyuepoglu, Ilker Y., Reichel, Martin, Traenkle, Christian, Siebzehnrubl, Florian ORCID: https://orcid.org/0000-0001-8411-8775, Buslei, Rolf, Bluemcke, Ingmar and Hahnen, Eric 2007. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Molecular Cancer Therapeutics 6 (6) , pp. 1745-1754. 10.1158/1535-7163.MCT-06-0763

Full text not available from this repository.

Abstract

Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity. Rapid proliferation and diffuse brain invasion of these tumors are likely to determine the unfavorable prognosis. Considering its promigratory properties, the transforming growth factor-beta (TGF-beta) signaling pathway has become a major therapeutic target. Analyses of resected glioma tissues revealed an intriguing correlation between tumor grade and the expression of TGF-beta(1-3) as well as their receptors I and II. Here, we analyzed the effects of peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists on glioma proliferation, migration, and brain invasion. Using an organotypic glioma invasion model, we show that micromolar doses of the PPAR-gamma activator troglitazone blocked glioma progression without neurotoxic damage to the organotypic neuronal environment observed. This intriguing antiglioma property of troglitazone seems to be only partially based on its moderate cytostatic effects. We identified troglitazone as a potent inhibitor of glioma cell migration and brain invasion, which occurred in a PPAR-gamma-independent manner. The antimigratory property of troglitazone was in concordance with the transcriptional repression of TGF-beta(1-3) and their receptors I and II and associated with reduced TGF-beta release. Due to its capacity to counteract TGF-beta release and glioma cell motility and invasiveness already at low micromolar doses, troglitazone represents a promising drug for adjuvant therapy of glioma and other highly migratory tumor entities.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences European Cancer Stem Cell Research Institute (ECSCRI)
Publisher:	American Association for Cancer Research
ISSN:	1535-7163
Last Modified:	25 Oct 2022 10:12
URI:	https://orca.cardiff.ac.uk/id/eprint/61401

Citation Data

Cited 38 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item